Fort Lee, NJ - May 7, 2003 - A recently published third edition of the American Heart Association's textbook, Hypertension Primer, is providing further support for the new non-drug hypertension treatment device, RESPeRATETM
This third edition includes a new chapter which reviews the link between respiration and blood pressure and suggests a physiological basis for the therapeutic effect of the RESPeRATETM previously demonstrated in six clinical studies.
"We now believe that significant blood pressure reductions delivered by RESPeRATETM may be explained at least in part by the reduced sympathetic outflow caused by the device's low frequency respiratory pacing technology, leading to the reduction of peripheral resistance and sensitization of the arterial baroreflex." Said Dr. Gianfranco Parati, one of the chapter's authors, who added that "the understanding of the physiological mechanism of action further supports the application of this device for the non-drug treatment of hypertension"
The RESPeRATETM, cleared by the FDA for the adjunctive treatment of hypertension, is gaining acceptance as a new non-drug modality in the treatment of the disease.
"Since the FDA clearance, we have received overwhelmingly good feedback from the thousands of patients and physicians who are successfully using RESPeRATETM" said Erez Gavish, CEO of InterCure, RESPeRATETM's manufacturer. "We are now seeing RESPeRATETM being incorporated into therapeutic guidelines and featured in a growing number of medical and popular publications. I'm confident that this important review will accelerate the adoption of the device into the standard of care."
For reprints of the chapter and additional information about RESPeRATETM see www.resperate.com/press or call Tom Kirwan at (201) 720-7750, ext. 7136.
Page: 1 Related medicine news :1
Contact: Tom Kirwan
. Hormonal treatment improves survival in high-risk prostate cancer patients2
. Chronic pain treatments more effective when taken together, new study shows3
. Brain activity prior to treatment flags vulnerability to antidepressant side effects4
. Cultural and social factors influence prostate cancer treatment5
. Research offers hope of new treatments for liver damage6
. First mouse model for multiple system atrophy points to new treatment targets for brain diseases7
. Stanford patient is first to test new treatment for peripheral arterial disease8
. Scientist works on innovative treatments for brain tumors9
. Blacks less likely to get expensive, newer heart treatments10
. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women11
. Study examines lessons learned at Africas first public antiretroviral treatment clinic